(Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over ...

Chinese stock markets returned to winning ways Thursday, closing with solid gains after China's central bank took action to ...

Highlights:,Intel Corporation is set to report its third-quarter 2024 financial results on Thursday, October 31, 2024, after market close.,An earnings conference call will follow at 2 p.m. PDT to ...

UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...

GSK (LSE: GSK) has settled 93% of Zantac (ranitidine) product liability cases in the USA, agreeing to pay up to $2.2 billion ...

Zantac settlement should ease investors’ nervousness but long-standing concerns about drugmaker’s pipeline remain ...

Lenders report that default rates on secured loans to UK households increased in Q3 2024 and are expected to increase again ...

Pharmaceutical giant GlaxoSmithKline (GSK) has agreed to pay up to $2.2 billion to settle most of lawsuits filed in U.S.

Highlights:,Tempest Therapeutics has entered into an agreement with Roche to advance amezalpat (TPST-1120) in combination ...

GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...